Porton Pharma Solutions

Porton Pharma Solutions, founded in 2005, operates as a global Contract Development and Manufacturing Organization (CDMO) specializing in small molecules, biologics, and advanced therapy medicinal products. The firm provides end-to-end pharmaceutical services, spanning from pre-clinical development to commercial-scale manufacturing. By integrating drug substance and product capabilities with advanced analytical solutions, the company supports pharmaceutical innovation while maintaining strict global regulatory compliance. Their technical infrastructure is designed to facilitate complex chemical synthesis and biological manufacturing processes for global clients.

The organization maintains a workforce of 1,000-5,000 employees, supporting operations across its primary facility in the Beibei District of Chongqing, China. Listed on the Shenzhen Stock Exchange under the ticker SZSE: PORTONPHARMA.COM, the company demonstrates significant market presence within the healthcare sector. Meet Porton Pharma Solutions's team to understand the organizational structure and leadership driving these technical operations. The company focuses on high-precision manufacturing services, ensuring that all drug intermediates and pharmaceutical products meet rigorous quality standards required for international market entry and clinical application.

Porton Pharma Solutions emphasizes environmental, social, and corporate governance (ESG) principles to drive sustainable development and long-term value creation. Their service portfolio includes custom drug development, regulatory support, and specialized R&D services tailored to the evolving needs of the pharmaceutical industry. With a revenue of $496.6M, the company continues to expand its technical capabilities in advanced therapy medicinal products. By leveraging its integrated platform, the firm provides scalable solutions that address the critical challenges of modern drug development, from initial research phases through to full-scale commercial production.